Nursing care
Respiratory Syncytial Virus Prevention, explained for the bedside and the exam
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
Respiratory syncytial virus prevention centres on hand hygiene, avoiding sick contacts and crowded settings during peak season, and monoclonal antibody prophylaxis for the highest-risk infants. RSV spreads easily via respiratory droplets and contaminated surfaces, so consistent handwashing and surface cleaning matter as much as any pharmacologic measure. Prevention, not treatment, is the priority because there's no specific antiviral cure for RSV.
The idea in one paragraph
RSV prevention is layered: behavioural measures for everyone, and a targeted pharmacologic measure for infants who face the highest risk of severe disease. Hand hygiene before and after contact with any infant, avoiding crowded indoor spaces during RSV season, and keeping sick siblings or visitors away from a newborn form the everyday backbone of prevention.
On top of that, a monoclonal antibody is available for infants who meet specific risk criteria — premature birth, chronic lung disease, congenital heart disease, or entering their first RSV season at high risk. This isn't a vaccine in the traditional sense; it's passive immunity given as a single injection, and it doesn't replace hand hygiene or avoiding exposure.
Why it matters clinically
RSV is the leading cause of bronchiolitis and pneumonia in infants under 12 months, and it's responsible for a significant share of paediatric hospital admissions every winter. Most healthy older children and adults experience RSV as a mild cold, which is exactly what makes it dangerous to infants — a parent or sibling with 'just a cold' can transmit a virus that puts a newborn in respiratory distress.
Premature infants and those with chronic lung or congenital heart disease lack the respiratory reserve to tolerate the airway inflammation and mucus plugging RSV causes. For this group, prevention carries more weight clinically than treatment, because supportive care is largely all that's available once infection sets in — supplemental oxygen, suctioning, and hydration, rather than a drug that clears the virus.
How to apply it at the bedside
Reinforce hand hygiene with every family you discharge with a newborn, and be specific: before touching the baby, after coming in from outside, after touching shared surfaces like doorknobs or shopping carts. Advise avoiding daycare, crowded shops, and large gatherings for young infants during peak RSV season, which typically runs autumn through spring depending on region.
Screen every eligible infant for monoclonal antibody prophylaxis at well-child visits and hospital discharge, particularly those born prematurely or with cardiac or pulmonary conditions. Document administration and counsel families that a single dose is intended to protect through one RSV season — it is not a substitute for hand hygiene, and the family should still avoid exposing the infant to sick contacts.
Where students get it wrong
The most common error is treating the monoclonal antibody as interchangeable with a vaccine that produces active immunity — it doesn't. It provides direct, passive protection that wanes over time, which is why it's given seasonally rather than as a one-time childhood immunisation.
Students also underweight hand hygiene and environmental measures in favour of the pharmacologic option, when the reverse is true: hand hygiene and avoiding crowds apply to every infant, while the monoclonal antibody is reserved for those who meet risk criteria. A question describing a healthy term infant with no risk factors is testing whether you'll default to behavioural prevention rather than assuming prophylaxis applies universally.
Worked examples
A nurse is discharging a term, healthy newborn in November. The correct teaching is hand hygiene, limiting visitors, and avoiding crowded indoor settings — the monoclonal antibody is not automatically indicated because the infant has no qualifying risk factors, though local guidance may still recommend it broadly during peak season.
A second scenario: a 4-month-old born at 30 weeks' gestation with chronic lung disease presents for a well-child visit in October, ahead of RSV season. Here the priority action is confirming and administering the monoclonal antibody, alongside reinforcing hand hygiene with the family, because prematurity and chronic lung disease place this infant in the highest-risk category.
How the exam tests it
NCLEX questions on RSV prevention usually present a scenario and ask you to identify the priority teaching or intervention, so read for risk factors first — gestational age, cardiac history, chronic lung disease — before deciding whether prophylaxis applies. If the stem describes a low-risk infant, the correct answer is almost always behavioural: hand hygiene, avoiding sick contacts, avoiding crowds.
Expect distractor answers that offer treatments for active RSV infection, such as antibiotics, when the question is actually asking about prevention. Antibiotics treat bacterial infection, not RSV, which is viral — this distinction is a common trap. Also expect questions that test whether you know the monoclonal antibody is not a vaccine and does not provide lifelong immunity.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pediatrics practice questions are the closest set to what this page covers.
Common questions
What is the main way to prevent RSV in infants?
Hand hygiene is the single most effective everyday measure, alongside avoiding crowded settings and sick contacts during RSV season. For the highest-risk infants, a monoclonal antibody adds an additional layer of passive protection.
Which infants qualify for RSV monoclonal antibody prophylaxis?
Infants born prematurely, those with chronic lung disease, and those with certain congenital heart conditions are the groups typically prioritised, especially heading into their first RSV season. Eligibility criteria can vary, so confirm against current local or national guidance.
Is the RSV monoclonal antibody the same as a vaccine?
No. It provides passive immunity through direct antibodies rather than stimulating the infant's own immune response, so protection is temporary and tied to a single RSV season rather than long-lasting.
How is RSV actually treated once an infant is infected?
Treatment is supportive — oxygen if needed, nasal suctioning, and hydration — because there's no antiviral that cures RSV. This is why prevention carries so much clinical weight for high-risk infants.
Why do healthy siblings pose a risk to a newborn during RSV season?
Older children and adults often experience RSV as a mild cold and can shed the virus while showing minimal symptoms. That mild presentation is enough to transmit a virus that causes severe bronchiolitis or pneumonia in a young infant.